Holen Sie sich die Stockscreener-App
11.92
4.02%
0.47
Schlusskurs vom Vortag:
$11.45
Offen:
$11.45
24-Stunden-Volumen:
27,416
Relative Volume:
0.37
Marktkapitalisierung:
$170.65M
Einnahmen:
$166.88M
Nettoeinkommen (Verlust:
$-74.18M
KGV:
-2.3511
EPS:
-5.07
Netto-Cashflow:
$1.14M
1W Leistung:
+6.91%
1M Leistung:
-19.80%
6M Leistung:
-31.35%
1J Leistung:
-55.36%
1-Tages-Spanne:
$11.38
$11.92
1-Wochen-Bereich:
$10.89
$11.92
52-Wochen-Spanne:
$10.89
$29.11
Anika Therapeutics Inc Stock (ANIK) Company Profile
Firmenname
Anika Therapeutics Inc
Sektor
Telefon
(781) 457-9000
Adresse
32 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie ANIK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
11.90 | 159.76M | 166.88M | -74.18M | 1.14M | -5.07 |
|
HLN
Haleon Plc Adr
|
11.06 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
170.67 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.8576 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.94 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.16 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-17 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-01 | Bestätigt | Barrington Research | Outperform |
| 2023-08-14 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | Fortgesetzt | Stephens | Equal-Weight |
| 2022-03-09 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | Eingeleitet | Stephens | Overweight |
| 2021-07-16 | Eingeleitet | UBS | Neutral |
| 2020-12-16 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | Hochstufung | Sidoti | Neutral → Buy |
| 2020-01-10 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | Eingeleitet | BWS Financial | Sell |
| 2019-09-24 | Bestätigt | Barrington Research | Outperform |
| 2019-09-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | Hochstufung | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | Herabstufung | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | Herabstufung | Sidoti | Buy → Neutral |
| 2018-07-27 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | Bestätigt | Barrington Research | Outperform |
| 2016-05-09 | Hochstufung | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | Bestätigt | Barrington Research | Outperform |
Alle ansehen
Anika Therapeutics Inc Aktie (ANIK) Neueste Nachrichten
Ameriprise Financial Inc. Boosts Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Long Term Trading Analysis for (ANIK) - news.stocktradersdaily.com
Jane Street Group LLC Acquires 3,065 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
BNP Paribas Financial Markets Increases Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Deutsche Bank AG Lowers Stock Position in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Orthopedic Regenerative Medicine Market Is Booming Worldwide | - openPR.com
Anika Therapeutics focuses on Hyalofast and Cingal advancements for 2025 growth - MSN
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ANIK Stock News - GuruFocus
Anika Therapeutics (ANIK) Sees Target Price Adjustment Amid Futu - GuruFocus
Tower Research Capital LLC TRC Acquires 2,326 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Anika Therapeutics (NASDAQ:ANIK) Downgraded by StockNews.com to “Hold” - Defense World
Anika Therapeutics (ANIK) Stock Maintains "Outperform" Rating De - GuruFocus
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Viscosupplementation Market: Executive Briefing & Strategic - openPR.com
Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates - MSN
Wells Fargo & Company MN Boosts Stock Position in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Investor Network: Anika Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2025 Earnings Call Transcript - Insider Monkey
Anika Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price - simplywall.st
Anika Therapeutics (ANIK) Faces OEM Challenges Amid Commercial G - GuruFocus
Dimensional Fund Advisors LP Sells 50,011 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Anika: Q1 Earnings Snapshot - News-Times
Anika Reports First Quarter 2025 Financial Results - GlobeNewswire
Anika Therapeutics Inc (ANIK) Q1 2025 Earnings Call Highlights: Strategic Growth Amidst Revenue ... - Yahoo Finance
Anika Therapeutics Inc (ANIK) Q1 2025 Earnings Call Highlights: Strategic Growth Amidst Revenue Challenges - GuruFocus
Earnings call transcript: Anika Therapeutics Q1 2025 misses forecasts, shares fall - Investing.com Nigeria
Anika Therapeutics Reports Mixed Q1 2025 Results - TipRanks
Anika Therapeutics’ Mixed Earnings Call Reveals Challenges and Growth - TipRanks
Anika Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0.28 M - GuruFocus
Anika Therapeutics (ANIK) Faces OEM Challenges Amid Commercial Growth - GuruFocus
Anika Therapeutics (ANIK) Reports Revenue Miss, Highlights Strat - GuruFocus
Anika Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0.28 Misses Estimate, Revenue of $26.2M Below Expectations - GuruFocus
Anika Therapeutics Posts Wider Loss From Cont. Ops. In Q1 - Nasdaq
Anika (ANIK) Revises 2025 Revenue and Adjusted EBITDA Outlook | ANIK Stock News - GuruFocus
Anika Therapeutics Reports 18% Growth in Commercial Channel Revenue for Q1 2025 Despite Overall Revenue Decline - Nasdaq
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2024 Earnings Call Transcript - MSN
Barclays PLC Buys 2,093 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Earnings To Watch: Anika Therapeutics Inc (ANIK) Reports Q1 2025 Result - GuruFocus
Exploring the Regenerative Medicine (Bone and Joint) Market: - openPR.com
Anika Reports Fourth Quarter and Full Year 2024 Financial Results - ADVFN
Anika to Participate in the Sidoti Virtual Investor Conference - GlobeNewswire
Regenerative Medicine (Bone and Joint) Market Generated - openPR.com
Is The Options Market Predicting A Spike In Anika Therapeutics Stock? - Barchart.com
Is the Options Market Predicting a Spike in Anika Therapeutics Stock? - Nasdaq
Invesco Ltd. Has $452,000 Stock Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Anika Therapeutics (ANIK) Projected to Post Quarterly Earnings on Friday - Defense World
Envestnet Asset Management Inc. Lowers Position in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Finanzdaten der Anika Therapeutics Inc-Aktie (ANIK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anika Therapeutics Inc-Aktie (ANIK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
| Nunes Anne | SVP, Chief Operations Officer |
Oct 01 '24 |
Option Exercise |
0.00 |
2,491 |
0 |
14,211 |
3.28%
2.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):